ReviewCells2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Journal for immunotherapy of cancer · 2024Trial
- Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- P2 X 7 receptor deficiency ameliorates high-fat-induced cardiac remodeling by improving oxidative stress through PI3K/AKT/GSK3β-mediated regulation of Nrf2.Journal of bioenergetics and biomembranes · 2026Article
- Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.NPJ precision oncology · 2025Article
- Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study.NPJ precision oncology · 2025Article
- Gene expression profiles, potential targets and treatments of cardiac remodeling.Molecular and cellular biochemistry · 2025Review
- Liquid biopsy in gastric cancer: A snapshot of the current state of the art.The journal of liquid biopsy · 2025Review
- FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Journal of Korean medical science · 2024Review
- Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.Scientific reports · 2024Article
- Role of molecular biology in the management of pancreatic cancer.World journal of gastrointestinal oncology · 2024Review
- Review
- Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.NPJ precision oncology · 2024Article
- Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications.The journal of liquid biopsy · 2023Review
- Genomic and Transcriptomic Research in the Discovery and Application of Colorectal Cancer Circulating Markers.International journal of molecular sciences · 2023Review
- Review
- Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects.Frontiers in molecular biosciences · 2023Review
- High-throughput extraction on a dynamic solid phase for low-abundance biomarker isolation from biological samples.Microsystems & nanoengineering · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels' size raise new questions in terms of detection of incidental germline alterations, occult malignancies and clonal hematopoiesis of indeterminate potential mutations. In this review, after a technological discussion and description of the common problematics encountered, we establish recommendations in properly using these FDA-approved tests in a molecular-tumor-board context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.